|
Joint Venture Announced
GlobeNewsWire (press release) We are very pleased to be joining with MediciNova in providing better solutions for asthma patients" MN-221 is a novel, highly selective, beta2-adrenergic receptor agonist in development as an intravenous treatment for acute exacerbations of asthma and … |
View full post on asthma – Google News